Age-related Survival Outcomes for Pancreatic Cancer by Age

2022 ◽  
Vol 2 (1) ◽  
pp. 71-77
Author(s):  
ALI ABBASZADEH KASBI ◽  
MOHAMMED ALI ASHARY ◽  
MIZBA BAKSH ◽  
SAMUEL NUSSBAUM ◽  
KRISTOPHER ATTWOOD ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Survival Rate ◽  
Older Patients ◽  
Poor Prognosis ◽  
Advanced Disease ◽  
National Cancer Data Base ◽  
Survival Outcome ◽  
Cancer Data ◽  
Age Related ◽  
Stage 1

Background/Aim: Pancreatic cancer has a very poor prognosis, though outcomes based on age are not well characterized. The aim of current study was to analyze the survival of patients with pancreatic cancer based on age. Patients and Methods: Using National Cancer Data Base (NCDB), we determined survival outcome based on age among patients with pancreatic cancer. Results: A total of 423,482 patients between 2004 and 2017 were included in the study. Patients aged between 18 and 40-years-old had the worst 3-year survival rate among stage 1 disease. Conversely, patients over 65-years-old had the worst 3-year survival rate and presented with more advanced disease (clinical stages 3 and 4). Conclusion: Older patients with more advanced disease had worse survival.

scholarly journals Variations in cancer centers’ use of cytology for the diagnosis of unresectable pancreatic cancer in the National Cancer Data Base

2016 ◽  
Vol 124 (11) ◽  
pp. 791-800 ◽  
Author(s):  
Ted Gansler ◽  
Stacey A. Fedewa ◽  
Chun Chieh Lin ◽  
Ahmedin Jemal ◽  
Elizabeth M. Ward
Keyword(s):  
Pancreatic Cancer ◽  
Data Base ◽  
National Cancer Data Base ◽  
Unresectable Pancreatic Cancer ◽  
Cancer Centers ◽  
Cancer Data

Endoscopic ultrasound-guided coeliac plexus block

2018 ◽  
Author(s):  
Arun Bhaskar
Keyword(s):  
Pancreatic Cancer ◽  
Poor Prognosis ◽  
Drug Delivery Systems ◽  
Advanced Disease ◽  
Celiac Plexus ◽  
Needle Placement ◽  
Ultrasound Guided ◽  
Tumour Infiltration ◽  
Plexus Block ◽  
Guide Needle

The landmark paper discussed in this chapter is ‘Endosonography-guided celiac plexus neurolysis’, published by Wiersema and Wiersema in 1996. Pain is one of its most distressing complaints of pancreatic cancer, affecting more than 80% of patients with advanced disease. However, the use of opioids and other drugs is often limited by undesirable side effects, which include somnolence, confusion, lethargy, and decreased cognitive function. Intrathecal drug delivery systems, although effective, are often deemed impractical in pancreatic cancer, due to its poor prognosis and the fact that it is often diagnosed late. Tumour infiltration of the coeliac plexus results in pain in the abdomen and back; thus, this area has often been targeted for analgesia via a neurolytic coeliac plexus block. The paper by Wiersema and Wiersema examines the efficacy of an approach that uses ultrasound to guide needle placement in celiac plexus neurolysis, in a study of 30 patients.

Systemic therapy use in stage IV pancreatic cancer: A population-based analysis using National Cancer Data Base (NCDB).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e15190-e15190
Author(s):  
Nabin Khanal ◽  
Smrity Upadhyay ◽  
Vijaya Raj Bhatt ◽  
Peter T. Silberstein
Keyword(s):  
Pancreatic Cancer ◽  
Data Base ◽  
Systemic Therapy ◽  
Stage Iv ◽  
Population Based ◽  
National Cancer Data Base ◽  
Cancer Data

Activity of RX-3117, an oral antimetabolite nucleoside, in patients with pancreatic cancer: Preliminary results of stage 1 of the phase 1a/2b.

2017 ◽  
Vol 35 (4_suppl) ◽  
pp. 445-445 ◽  
Author(s):  
Drew W. Rasco ◽  
Christine Peterson ◽  
Ely Benaim ◽  
Jaime R. Merchan
Keyword(s):  
Pancreatic Cancer ◽  
Primary Endpoint ◽  
Stable Disease ◽  
Performance Status ◽  
Single Agent ◽  
Advanced Pancreatic Cancer ◽  
Metastatic Pancreatic Cancer ◽  
Cancer Data ◽  
Phase 1B ◽  
Stage 1

445 Background: RX-3117 is an oral smallmolecule antimetabolite, cyclopentyl pyrimidyl nucleoside that is activated by uridine cytidine kinase 2. RX-3117 has shown efficacy in xenograft models of gemcitabine resistant pancreatic, bladder and colorectal cancer. Data from stage 1 of the Phase 1b/2a clinical study of RX3117 as a single agent in subjects with metastatic pancreatic cancer is described below. Methods: Stage 1 of the Phase 1b/2a study (NCT02030067) is designed to evaluate safety, tolerability and efficacy following treatment with 700 mg administered orally once-daily for 5 consecutive days with 2 days off per week for 3 weeks with 1 week off in each 4 week cycle in a 2-stage Simon design. Eligible subjects (aged ≥ 18 years) were those with relapsed/refractory metastatic pancreatic cancer. The primary endpoint is a ≥ 20% (2 out of 10 subjects) rate of progression free survival (PFS) benefit (i.e., proportion of subjects with stable disease for at least 4 months) and/or a 10% (1 of 10 subjects) with a partial response rate or better. Results: As of Sep 2016, 8 out of 10 subjects have been enrolled (4 females, 4 males), the mean age was 70 years, ECOG performance status was 1 and 5 subjects had received more than 4 prior therapies. Two subjects met the primary endpoint of stable disease with a duration of 140-168 days at the time of this submission. The most frequent adverse events were moderate to severe anemia, mild to moderate fatigue, abdominal pain and diarrhea. Conclusions: This ongoing trial shows an early efficacy signal where RX-3117 is active against advanced pancreatic cancer. As the primary endpoint has been achieved, the study will now move to stage 2 where an additional 40 subjects with advanced pancreatic cancer will be enrolled. Clinical trial information: NCT02030067.

scholarly journals 1037 Increased Pancreatic Cancer Survival with Greater Lymph Node Retrieval in the National Cancer Data Base

2016 ◽  
Vol 150 (4) ◽  
pp. S1203
Author(s):  
Carlo M. Contreras ◽  
Chee P. Lin ◽  
Robert Oster ◽  
Sushanth M. Reddy ◽  
Thomas N. Wang ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Lymph Node ◽  
Data Base ◽  
Cancer Survival ◽  
National Cancer Data Base ◽  
Cancer Data ◽  
Lymph Node Retrieval

scholarly journals Umbilical mass as the sole presenting symptom of pancreatic cancer: a case report

2004 ◽  
Vol 59 (4) ◽  
pp. 198-202 ◽  
Author(s):  
Fábio Crescentini ◽  
Fernanda Deutsch ◽  
Carlos Walter Sobrado ◽  
Sérgio de Araújo
Keyword(s):  
Pancreatic Cancer ◽  
Poor Prognosis ◽  
Palliative Chemotherapy ◽  
Advanced Disease ◽  
Immunohistochemical Analysis ◽  
Abdominal Discomfort ◽  
Clinical Suspicion ◽  
Clinical Staging ◽  
Metastatic Involvement ◽  
Sister Mary Joseph

Umbilical nodes are rare. The metastatic involvement of the region was first described in 1846. Sister Mary Joseph was the first observer to establish the correlation between carcinomas and umbilical nodes. The umbilical node may be the sole presenting sign of cancer and is usually associated with advanced disease and poor prognosis. A 64-year-old woman, previously healthy, presented vague abdominal discomfort and a hard umbilical nodule for 1 week, which was first diagnosed as an incarcerated umbilical hernia. She underwent a new clinical assessment and biopsy. After immunohistochemical analysis and computerized tomography, she was diagnosed with pancreatic cancer. The clinical staging showed advanced disease with distant metastasis. She received palliative chemotherapy. After 8 months, she was alive in poor clinical condition. Clinical suspicion should lead to a careful additional evaluation whenever an umbilical nodule presents with malignant signs.

Disparities in the Age-Related Rates of Colorectal Cancer in the United States

2017 ◽  
Vol 83 (6) ◽  
pp. 640-647 ◽  
Author(s):  
Emmanuel Gabriel ◽  
Katherine Ostapoff ◽  
Kristopher Attwood ◽  
Eisar Al-Sukhni ◽  
Patrick Boland ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
Age Groups ◽  
The United States ◽  
National Cancer Data Base ◽  
Stage Iii ◽  
Cancer Data ◽  
Age Related ◽  
Rate Of Increase ◽  
Hispanic Patients

The incidence of colorectal cancer (CRC) among Americans under the age of 50 years is increasing. The purpose of this study was to identify racial and socioeconomic disparities associated with this trend. The National Cancer Data Base was used to identify patients with CRC from 1998 to 2011. Patients were stratified by age (<50 versus >60 years), with ages 50 to 60 years omitted from the analysis to minimize overlapping trends between the two age groups. Relative frequencies (RFs) by year were plotted against demographic variables. Changes in RF over time and intervals from diagnosis to treatment (including surgery and chemotherapy) were compared. A total of 1,213,192 patients were studied; 885,510 patients with colon cancer and 327,682 with rectal or rectosigmoid cancer. Patients <50 years had higher RF for stage III/IV CRC compared with >60 years, with the highest rate of increase in stage III colon cancer (0.198% per year). Patients <50 years had higher RF for CRC if they were African-American or Hispanic. Hispanic patients <50 years had the highest rates of increase for both colon (RF = 0.300% per year) and rectal cancer (RF = 0.248% per year). Compared with race, other variables including education and income were not found to have as strong an association on age-related rates of CRC. No clinically significant differences were observed for time from diagnosis to treatment in either age group. Important racial disparities are associated with differences in age-related CRC rates, warranting further investigation to develop improved strategies for the earlier detection of CRC in these populations.

Sign in / Sign up

Export Citation Format

Share Document